SCHEMBL3237671

SCHEMBL3237671

O=C(NCc1ccc(Cl)c(Cl)c1)c1ccc(C(=O)N2CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.59
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KLKB1 P03952 1/20 0.53
KLK1 P06870 1/20 0.53
EPHX2 P34913 2/20 0.53
MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242896 0.89 MAPT (0.54) HPGDALDH1A1MAPTL3MBTL1KLKB1
SCHEMBL3259879 0.86 MAPT (0.70) HPGDCA12CA1CA2CA9
SCHEMBL3237674 0.85 HPGD (0.59) HPGDCA12CA1CA2CA9
SCHEMBL3241841 0.84 HSD11B1 (0.59) ALDH1A1MAPTL3MBTL1KLKB1KLK1
SCHEMBL3268296 0.84 CA12 (0.47) HPGDCA12CA1CA2CA9
SCHEMBL3808704 0.82 HPGD (0.64) HPGDHDAC1HDAC8HDAC6ALDH1A1
SCHEMBL8108036 0.79 EPHX2 (0.79) HPGDHDAC4HDAC1HDAC7HDAC11
SCHEMBL9120814 0.78 HDAC4 (0.67) HPGDHDAC4HDAC1HDAC7HDAC11
SCHEMBL6280995 0.78 HPGD (0.96) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL13026611 0.77 LMNA (0.65) HPGDHDAC4HDAC1HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 HPGD 3739/4885HDAC4 1184/4885HDAC1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.